Peter Harper

11.5k total citations · 3 hit papers
139 papers, 7.7k citations indexed

About

Peter Harper is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Peter Harper has authored 139 papers receiving a total of 7.7k indexed citations (citations by other indexed papers that have themselves been cited), including 75 papers in Oncology, 60 papers in Pulmonary and Respiratory Medicine and 31 papers in Surgery. Recurrent topics in Peter Harper's work include Lung Cancer Research Studies (28 papers), Lung Cancer Treatments and Mutations (25 papers) and Neuroendocrine Tumor Research Advances (18 papers). Peter Harper is often cited by papers focused on Lung Cancer Research Studies (28 papers), Lung Cancer Treatments and Mutations (25 papers) and Neuroendocrine Tumor Research Advances (18 papers). Peter Harper collaborates with scholars based in United Kingdom, United States and Canada. Peter Harper's co-authors include David Cunningham, Allan B. Okey, David S. Riddick, Tamas Hickish, A. Norman, Timothy Iveson, Stephen Spiro, Juan W. Valle, M. Nicolson and Janine Mansi and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Peter Harper

136 papers receiving 7.5k citations

Hit Papers

Randomized trial comparing epirubicin, cisplatin, and flu... 1997 2026 2006 2016 1997 2009 2009 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer.
    1997 691 citations Andrew Webb, David Cunningham et al. Journal of Clinical Oncology profile →
  2. Phase III Randomized Comparison of Gemcitabine Versus Gemcitabine Plus Capecitabine in Patients With Advanced Pancreatic Cancer
    2009 602 citations David Cunningham, Ian Chau et al. Journal of Clinical Oncology profile →
  3. Evaluation of New Platinum-Based Treatment Regimens in Advanced-Stage Ovarian Cancer: A Phase III Trial of the Gynecologic Cancer InterGroup
    2009 500 citations Michael A. Bookman, Mark F. Brady et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Peter Harper United Kingdom 45 4.7k 3.2k 1.9k 1.4k 1.0k 139 7.7k
Irene Floriani Italy 47 3.3k 0.7× 2.3k 0.7× 1.8k 1.0× 1.2k 0.8× 605 0.6× 159 8.3k
Vittorio Gebbia Italy 40 4.2k 0.9× 2.2k 0.7× 1.3k 0.7× 1.0k 0.7× 627 0.6× 290 7.0k
A.T. van Oosterom Netherlands 41 3.8k 0.8× 2.9k 0.9× 2.3k 1.2× 1.8k 1.3× 264 0.3× 177 7.8k
Jee Hyun Kim South Korea 43 5.2k 1.1× 2.9k 0.9× 1.8k 1.0× 1.5k 1.1× 429 0.4× 320 8.1k
Ashley E. Winkler United States 10 3.9k 0.8× 2.5k 0.8× 1.4k 0.8× 1.1k 0.8× 731 0.7× 12 7.3k
Pierre Kerbrat France 42 4.6k 1.0× 2.1k 0.7× 2.4k 1.3× 1.1k 0.8× 452 0.4× 189 8.3k
David Malka France 57 5.5k 1.2× 2.6k 0.8× 4.1k 2.2× 1.1k 0.8× 1.4k 1.4× 233 9.3k
Scott Wadler United States 43 4.5k 1.0× 1.9k 0.6× 1.9k 1.0× 2.0k 1.5× 517 0.5× 192 8.1k
Louise B. Grochow United States 32 4.0k 0.9× 1.5k 0.5× 1.9k 1.0× 1.3k 1.0× 786 0.8× 59 6.6k
H. Cortés-Funes Spain 44 6.4k 1.4× 2.6k 0.8× 2.1k 1.1× 1.8k 1.3× 516 0.5× 192 9.6k

Countries citing papers authored by Peter Harper

Since Specialization
Citations

This map shows the geographic impact of Peter Harper's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Harper with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Harper more than expected).

Fields of papers citing papers by Peter Harper

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Harper. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Harper. The network helps show where Peter Harper may publish in the future.

Co-authorship network of co-authors of Peter Harper

This figure shows the co-authorship network connecting the top 25 collaborators of Peter Harper. A scholar is included among the top collaborators of Peter Harper based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter Harper. Peter Harper is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Eeles, Rosalind A., James P. Morden, Martin Gore, et al.. (2016). Adjuvant Hormone Therapy May Improve Survival in Epithelial Ovarian Cancer. Obstetrical & Gynecological Survey. 71(4). 223–224.
2.
3.
Bookman, Michael A., Mark F. Brady, William P. McGuire, et al.. (2009). Evaluation of New Platinum-Based Treatment Regimens in Advanced-Stage Ovarian Cancer: A Phase III Trial of the Gynecologic Cancer InterGroup. Journal of Clinical Oncology. 27(9). 1419–1425. 500 indexed citations breakdown →
4.
5.
Nackaerts, Kristiaan, Corey J. Langer, Peter Harper, et al.. (2008). International Consensus Panel Recommendations for the diagnosis of bone metastases (METS) from lung cancer (LC). Journal of Thoracic Oncology. 3(4). 4 indexed citations
6.
Hughes, Simon, Aisha Miah, Shahreen Ahmad, et al.. (2008). A Brief Report on the Safety Study of Induction Chemotherapy Followed by Synchronous Radiotherapy and Cetuximab in Stage III Non-small Cell Lung Cancer (NSCLC): SCRATCH Study. Journal of Thoracic Oncology. 3(6). 648–651. 52 indexed citations
7.
Hughes, Simon, Aisha Miah, Shahreen Ahmad, et al.. (2007). P2-184: Safety study of induction chemotherapy followed by Synchronous Radiotherapy (RT) and cetuximab in stage III non-small cell lung cancer (NSCLC): SCRATCH study (Cohort I). Journal of Thoracic Oncology. 2(8). S642–S643. 1 indexed citations
8.
Ross, Paul J., David Cunningham, Alyson Norman, et al.. (2006). Efficacy and tolerability of chemotherapy in elderly patients with advanced oesophago-gastric cancer: A pooled analysis of three clinical trials. European Journal of Cancer. 42(7). 827–834. 74 indexed citations
9.
Steer, Christopher & Peter Harper. (2002). Gastro-oesophageal complications in patients receiving cancer therapy: the role of proton pump inhibitors.. PubMed. 14 Suppl 1. S17–21. 11 indexed citations
10.
Plunkett, T.A., et al.. (2001). Management of Merkel cell carcinoma. Expert Review of Anticancer Therapy. 1(3). 441–445. 9 indexed citations
11.
Harper, Peter, Christos S. Karapetis, Desmond Yip, et al.. (2001). Epirubicin, Cisplatin, and Prolonged or Brief Infusional 5-Fluorouracil in the Treatment of Carcinoma of Unknown Primary Site. Medical Oncology. 18(1). 23–32. 2 indexed citations
12.
Hain, Sharon F., Michael O’Doherty, A.R. Timothy, et al.. (2000). Fluorodeoxyglucose positron emission tomography in the evaluation of germ cell tumours at relapse. British Journal of Cancer. 83(7). 863–869. 82 indexed citations
13.
Waters, Justin S., A. Norman, David Cunningham, et al.. (1999). Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial. British Journal of Cancer. 80(1-2). 269–272. 221 indexed citations
14.
15.
Twelves, Chris, J M Goldman, C. M. Ash, et al.. (1991). Sequential chemotherapy in good-prognosis patients with small-cell lung cancer. Cancer Chemotherapy and Pharmacology. 28(2). 139–141. 13 indexed citations
16.
Coleman, Robert E., et al.. (1989). A phase II study of mitozantrone in advanced carcinoma of the ovary. Cancer Chemotherapy and Pharmacology. 24(3). 200–202. 10 indexed citations
17.
18.
Souhami, R L, D M Geddes, Stephen Spiro, et al.. (1984). Radiotherapy in small cell cancer of the lung treated with combination chemotherapy: a controlled trial.. BMJ. 288(6431). 1643–1646. 104 indexed citations
19.
Harper, Peter, C Trask, & R L Souhami. (1984). Avascular necrosis of bone caused by combination chemotherapy without corticosteroids.. BMJ. 288(6413). 267–268. 71 indexed citations
20.
Harper, Peter, et al.. (1983). Total parenteral nutrition: value of a standard feeding regimen.. BMJ. 286(6374). 1323–1327. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Irene Floriani Breakdown of academic impact, for papers by Vittorio Gebbia Breakdown of academic impact, for papers by A.T. van Oosterom Breakdown of academic impact, for papers by Jee Hyun Kim Breakdown of academic impact, for papers by Ashley E. Winkler Breakdown of academic impact, for papers by Pierre Kerbrat Breakdown of academic impact, for papers by David Malka Breakdown of academic impact, for papers by Scott Wadler Breakdown of academic impact, for papers by Louise B. Grochow Breakdown of academic impact, for papers by H. Cortés-Funes
Rankless by CCL
2026